Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and efficacy endpoints, positioning the company to seek approval once the analysis is complete. The ...

Lilly is currently waiting for the U.S. Food and Drug Administration’s (FDA’s) decision to expand the use of tirzepatide to ...

Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

An unhealthy diet and an indolent life are well known causes of heart disease and stroke. But sleep apnea—where people ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

I’m sorry to hear your CPAP mask is keeping you awake at night, but I’m happy to hear that you’re addressing your obstructive ...

Think of the heart as a pump that works tirelessly every day. But sometimes, this pump starts to weaken, which is what ...

This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...

LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary ...

The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea (OSA ... data to the U.S. Food and Drug Administration (FDA) ...

It's been more than a year since Apple Watch Ultra 2 launched, and we've had the wearable that's only gotten better on our ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire,” or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...